's Avatar

@mattherder.bsky.social

law prof

37 Followers  |  43 Following  |  35 Posts  |  Joined: 05.02.2025  |  2.3393

Latest posts by mattherder.bsky.social on Bluesky

Preview
Ottawa abusing access to information law to avoid releasing documents, watchdog says The Information Commissioner is calling on the government to stop relying on legal exemptions she says are overused

Ottawa abusing access to information law to avoid releasing documents, watchdog says. The Information Commissioner is calling on the government to stop relying on legal exemptions she says are overused.
www.theglobeandmail.com/politics/art... via @theglobeandmail.com #FOI #SecretCanada

28.09.2025 23:50 β€” πŸ‘ 21    πŸ” 6    πŸ’¬ 0    πŸ“Œ 0
Preview
Biopharmaceuticals, Financialization & Nationalism in the Age of COVID-19 - Healthy Debate Canada spent a lot of money on a COVID-19 therapeutic that has been aΒ flop. The deal reflects the financialized state of drug development and the nation-state's failure to stop it.

It *could* have, yes, but the only kinds of conditionalities GoC imposed on the reams of funding it dolled out during Covid related to domestic manufacturing. See, for example,

www.hilltimes.com/story/2021/0...

pubmed.ncbi.nlm.nih.gov/37579382/

healthydebate.ca/2021/03/topi...

29.09.2025 11:20 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Rights Groups Call for Probe of World Bank Hospital Funding More than 50 human rights organizations, nonprofits and international development experts are calling on the World Bank to investigate its health-care investments in Africa and Asia, citing Bloomberg ...

🚨@WorldBank's mission is to fight poverty, yet @IFC_org is funding high-end unaffordable hospitals & exacerbating inequality? This approach will not deliver on the WBs target to reach 1.5 billion with access to quality healthcare! #UHC #PeopleOverProfits www.bloomberg.com/news/article...

23.09.2025 08:06 β€” πŸ‘ 4    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

Live in the Halifax area but concerned about global health?

This talk on Thursday featuring @stephanienolen.bsky.social is NOT to be missed!

22.09.2025 16:04 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

New paper alert! Led by @hollylynchez.bsky.social we report findings from interviews with reps from @fda.gov, pharma, patient orgs + payers about the challenges involved in securing rigorous safety/efficacy evidence re: drugs granted accelerated approval.

See the thread below for details.

22.09.2025 10:56 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Flexibility Over Rigor: Stakeholder Acceptance of the Limitations of Confirmatory Studies Following Accelerated Approval Despite the importance of postmarketing requirements (PMRs) following accelerated approval and well-recognized shortcomings in their rigor and timeliness,

academic.oup.com/healthaffair...

20.09.2025 12:33 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
RFK Jr., American Psycho He needs to go. Now.

Good morning America. Happy Monday. And #RFKJr still needs to go. Now. My piece in @thenation.com last week. www.thenation.com/article/soci...

08.09.2025 09:50 β€” πŸ‘ 564    πŸ” 156    πŸ’¬ 20    πŸ“Œ 5

I’ll answer if you say who you are.

05.09.2025 23:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

This is a fake account and pure misogyny. I’m at a complete loss.

05.09.2025 22:45 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Paul Magennis and Kim Carlson continue to do great work responding to irresponsible journalism spreading myths, mis-, and disinformation about MAiD in Canada.

19.08.2025 19:34 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0
Meet The NYU Prof Suing Over Feds' Deal In HIV Drug Fight - Law360 Healthcare Authority For a large part of his life, New York University associate law professor Chris Morten dreamed of becoming a scientist. Today, he's representing a health equity advocacy group seeking access to the se...

I got to talk with Gianna Ferrarin (β€ͺ@law360.bsky.social‬) about the new FOIA case my clinic is litigating (PrEP4All v. HHS & DOJ), 7 years (!) of work with @prep4allnow.bsky.social on PrEP patents, and my path from science to practice to clinical teaching.
πŸ”—: www.law360.com/healthcare-a...

20.08.2025 14:39 β€” πŸ‘ 6    πŸ” 3    πŸ’¬ 0    πŸ“Œ 1
Lenacapavir to Prevent HIV Infection: Updated Estimated Costs of Production for Generic Treatments Background: Lenacapavir/Sunlencaβ„’ administered every 26 weeks as Pre-exposure Prophylaxis (PrEP) reduces HIV transmission to nearly zero. Affordable lenacapavir

Link to the pre-print here: papers.ssrn.com/sol3/papers....

20.06.2025 14:02 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
β€˜HIV-ending’ drug could be made for just $25 per patient a year, say researchers As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it β€˜available and affordable for all who need it’

Incredible piece of work by Andy Hill & colleagues showing that #Lenacapavir could be made for just $25 yet the company marketing it will charge $25,000 per patient

www.theguardian.com/society/2025....

17.06.2025 12:40 β€” πŸ‘ 5    πŸ” 4    πŸ’¬ 2    πŸ“Œ 2
Preview
South Africa Built a Medical Research Powerhouse. Trump Cuts Have Demolished It.

@stephanienolen.bsky.social's piece on the destruction of the South African biomedical research effort by the Trump Administration is a must-read. Please circulate. This is a disaster for South Africa AND the world. www.nytimes.com/2025/06/17/h...

17.06.2025 10:27 β€” πŸ‘ 126    πŸ” 95    πŸ’¬ 4    πŸ“Œ 4
Post image

Just shy of 3 years ago the BC gov settled its case against #PurduePharma. In addition to the $ secured, "additional benefits" in the form of "access to information + documents" were promised to be made public.

Has any of that info ever emerged? Asking for a friend

news.gov.bc.ca/releases/202...

12.06.2025 15:21 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Safe supply an effective treatment tool despite political backlash, study confirms - Healthy Debate New study shows that safe supply may be a more effective treatment option than methadone for those most at risk,.

#SaferSupply an effective treatment tool despite political backlash. New study shows safe opioid supply more effective than opioid agonist therapies, by @maddidellplain.bsky.social healthydebate.ca/2025/06/topi... via @healthydebate.bsky.social

12.06.2025 14:56 β€” πŸ‘ 23    πŸ” 11    πŸ’¬ 0    πŸ“Œ 0

Wow, and among the questionable folks that replaced them is Robert Malone, a scientist who still appears to be bitter for -- in his words in the article in @nature.com below -- being "written out of the history" of mRNA.

Talk about an agenda.

www.nature.com/articles/d41...

12.06.2025 12:39 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

🌍Transparency in the pharmaceutical sector is not only a matter of democratic accountability β€” it’s a global health imperative.

πŸ“…Join us on June 12th for an online event exploring how civil society is advancing pharmaceutical transparency with cases from South Africa, Colombia, and Spain

10.06.2025 12:52 β€” πŸ‘ 4    πŸ” 2    πŸ’¬ 1    πŸ“Œ 0
Law and Global Governance of Infectious Disease: Access to Medicines on COVID-19, AIDS, and Beyond | Journal of Law, Medicine & Ethics | Cambridge Core Law and Global Governance of Infectious Disease: Access to Medicines on COVID-19, AIDS, and Beyond

Must Read:

Law & Global Governance of Infectious Disease: Access to Medicines on COVID, AIDS, & Beyond
Via:
American Society of Law, Medicine & Ethics Journal
Cambridge Univ. Press
@ASLMENews

Matthew Kavanagh
Luis G Abinader
Fatima Hassan
Eric Friedman

Link:
www.cambridge.org/core/journal...

15.05.2025 07:18 β€” πŸ‘ 3    πŸ” 3    πŸ’¬ 1    πŸ“Œ 0

To be clear, I don't know whether NIH has a claim to Ridgeback's PRV if/when it's sold. The license terms are not, to my knowledge, publicly available b/c Ridgeback is a private company.

Maybe it's time to FOIA NIH to see how many PRVs it has a financial stake in.

/end.

14.05.2025 17:36 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

That might explain why many of the deals, like the one NIH struck with Ridgeback, end up being exclusive. NIH wants a cut of the PRV if the product is approved. In return, the company gets exclusivity. /7

14.05.2025 17:36 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

I learned recently that the US National Institutes of Health often takes a financial stake in any PRVs that the IP they license out. /6

14.05.2025 17:36 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

We should expect nothing less when we use the market to solve public health problems.

But what if the state, as the holder of the IP, approaches its licensing negotiations with the financial rewards foremost in mind? /5

14.05.2025 17:36 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Preview
Neglected Tropical Disease Treatment Development Before and After an FDA Incentive Program This study uses commercial pharmaceutical database data to evaluate the number of new drugs and vaccines for neglected tropical diseases entering phase 1 clinical trials before and after introduction ...

Such PRVs can be bought and sold, in some cases, for hundreds of millions, and used by the purchaser to expedite FDA review of a drug targeting a much more lucrative disease.

jamanetwork.com/journals/jam... /4

14.05.2025 17:36 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Preview
Issuance of Priority Review Voucher; Material Threat Medical Countermeasure Product; EBANGA The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a material threat medical countermeasure (MCM) product application. The Federal Food, D...

I wonder tho whether we are missing key details.

Ebanga -the brandname for the drug licensed to Ridgeback Biotherapeutics- might not command much of a market outside of LMICs.

But it has garnered a "priority review voucher" since earning FDA approval

www.federalregister.gov/documents/20.... /3

14.05.2025 17:36 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Preview
KEI Comments on NIH Exclusive License to Ridgeback for FDA-approved Ebola Treatment - Knowledge Ecology International (Update: On April 30, 2021, the NIH sent a response to KEI’s comments.) On March 30, 2021, Knowledge Ecology International (KEI) filed comments regarding the National Institute of Health (NIH) Nationa...

As KEI explains here, it's far from clear that an exclusive license was necessary given that the product was already on the market!

www.keionline.org/35778 /2

14.05.2025 17:36 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

Quick follow up thread:

It is always baffling *at first* to learn that an important health intervention like an Ebola therapeutic - substantially developed by the public sector - has been licensed exclusively to a private company..../1

14.05.2025 17:36 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0
Preview
From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine The discovery and development of the Ebola rVSV-ZEBOV vaccine challenge the common assumption that the research and development for innovative therapeutic products and vaccines is best carried out by ...

This is sadly a very familiar story. See for eg, the story of the rVSV-ZEBOV Ebola vaccines.

pmc.ncbi.nlm.nih.gov/articles/PMC...

14.05.2025 17:05 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Yuanquiong Hu from @msf.ca access walking us through the long road to Ebola therapeutics, detailing how publicly funded science came to be privately controlled.

14.05.2025 17:05 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 1    πŸ“Œ 1
Post image

Andy Hill breaking down, with gut wrenching clarity, the difference between the price (charged by big pharma) & (far lower) cost of making medicines @itpc.bsky.social

14.05.2025 10:40 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

@mattherder is following 20 prominent accounts